Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[177Lu]Lu-NNS309 in Advanced Pancreatic, Lung, Breast and Colorectal Cancers
NCT06562192Phase 1Recruiting
- Sponsor
- Novartis
- Start
- Oct 2024
- Primary completion
- Jan 2031
- Modality
- Antibody-Radionuclide Conjugates, Peptide-Drug Conjugates
- Countries
- 10
01
Overview
Phase 1, open-label, single-arm trial of [177Lu]Lu-NNS309 in pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), breast cancer and 2 more, sponsored by Novartis. Primary endpoints: Dose Limiting Toxicities at 6 weeks, Adverse Events and Serious Adverse Events at 42 months and 2 more. Started Oct 2024; status: recruiting.
02
Drugs
[177Lu]Lu-NNS309
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)non-small cell lung cancer (NSCLC)breast cancertriple-negative breast cancer (TNBC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06562192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06562192.